Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects

Empagliflozin (EMPA), a drug approved for type 2 diabetes management, reduced cardiovascular death but is unknown if it reduces myocardial infarction. We sought to investigate: (i) the effect of EMPA on myocardial function and infarct size after ischemia/reperfusion in mice fed with western diet (WD...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreadou, Ioanna, Efentakis, Panagiotis, Balafas, Evangelos, Togliatto, Gabriele, Davos, Constantinos H., Varela, Aimilia, Dimitriou, Constantinos A., Nikolaou, Panagiota-Efstathia, Maratou, Eirini, Lambadiari, Vaia, Ikonomidis, Ignatios, Kostomitsopoulos, Nikolaos, Brizzi, Maria F., Dimitriadis, George, Iliodromitis, Efstathios K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742117/
https://www.ncbi.nlm.nih.gov/pubmed/29311992
http://dx.doi.org/10.3389/fphys.2017.01077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742117/
https://www.ncbi.nlm.nih.gov/pubmed/29311992
http://dx.doi.org/10.3389/fphys.2017.01077

Ejemplares similares